Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Astrana Health (ASTH)

Astrana Health Q1 revenue rises 53% to $620.4 million; profit falls

Mixed Impact 3 of 5 earnings Written later

Astrana Health reported first-quarter 2025 total revenue of $620.4 million, up 53% from a year earlier, driven by its Care Partners segment. Net income attributable to the company fell to $6.7 million, or $0.14 per diluted share, from $14.8 million, or $0.31 per share, and Adjusted EBITDA declined to $36.4 million from $42.2 million, so shareholders face higher revenue alongside lower profit. The company reiterated its full-year 2025 guidance and issued second-quarter guidance.

Key points

  • Total revenue $620.4 million, up 53% from $404.4 million; Care Partners revenue $601.0 million, up 57%
  • Net income attributable to Astrana $6.7 million vs. $14.8 million; diluted EPS $0.14 vs. $0.31
  • Adjusted EBITDA $36.4 million vs. $42.2 million; Adjusted EBITDA margin 6% vs. 10%
  • Q2 2025 guidance: revenue $615 million to $655 million and Adjusted EBITDA $45 million to $50 million; full-year 2025 revenue $2.5 billion to $2.7 billion and Adjusted EBITDA $170 million to $190 million, reiterated

The filing

CompanyAstrana Health (ASTH)
Form8-K, current report
Filed with the SECMay 8, 2025, 4:15 PM ET
Accession number0001104659-25-046125

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:54 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 08, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.